A Phase 2 interventional study of ARQ-151 cream 0.3% in Psoriasis and Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 17 sites in 3 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2023-12-15.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.
Among the 17 studies testing roflumilast in Psoriasis, this one is the 13th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 2, and was the 10th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Modern Research Associates, PLLC · Sites in United States
Ahmed Ibrahim · Sites in Egypt
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 46 across the 17 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 9 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
12 studies in Psoriasis by Arcutis Biotherapeutics, Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 11th largest by enrollment, is one of 4 that started in 2020, is one of 5 in phase 2, and was the 9th registered.
Arcutis Biotherapeutics, Inc.’s Psoriasis studies by the year they started, since 2017.
1 of the studies testing roflumilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725822Modern Research Associates, PLLCAn Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing roflumilast in Psoriasis, from their registry updates:
Among Arcutis Biotherapeutics, Inc.’s 12 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
Drug: ARQ-151 cream 0.3%
ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Also known as: Topical roflumilast
Plasma Concentration of ARQ-151 Cream 0.3%
Plasma levels of circulating roflumilast were determined at 2 points in the study.
Time frame: Predose on Days 14 and 28
Plasma Concentration of the Roflumilast Major N-oxide Metabolite
Plasma levels of circulating the roflumilast major N-oxide metabolite were determined at 2 points in the study.
Time frame: Predose on Days 14 and 28
Number of Participants With ≥1 Adverse Event (AE)
The number of participants with adverse events during the treatment period is reported. An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research.
Time frame: Up to 28 days
Number of Participants With Application Site Reactions
The number of subjects experiencing an application site skin reactions by investigator assessment is reported. The investigator assessed for erythema prior to that day's application of investigational product.
Time frame: Baseline (Day 1), Day 7, and Day 14
| Milestone | ARQ-151 Cream 0.3% |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
Plasma levels of circulating roflumilast were determined at 2 points in the study.
| ng/mL | ARQ-151 Cream 0.3% |
|---|---|
| Day 14 | 3.15 ± 3.64 |
| Day 28 | 1.68 ± 1.57 |
Plasma levels of circulating the roflumilast major N-oxide metabolite were determined at 2 points in the study.
| ng/mL | ARQ-151 Cream 0.3% |
|---|---|
| Day 14 | 28.9 ± 41.1 |
| Day 28 | 15.7 ± 15.8 |
The number of participants with adverse events during the treatment period is reported. An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research.
| Participants | ARQ-151 Cream 0.3% |
|---|---|
| Number of Participants With ≥1 Adverse Event (AE) | 4 |
The number of subjects experiencing an application site skin reactions by investigator assessment is reported. The investigator assessed for erythema prior to that day's application of investigational product.
| Participants | ARQ-151 Cream 0.3% |
|---|---|
| Day 1: No erythema | 18 |
| Day 1: Minimal erythema | 0 |
| Day 1: Definite erythema | 1 |
| Day 7: No erythema | 17 |
| Day 7: Minimal erythema | 3 |
| Day 7: Definite erythema | 0 |
| Day 14: No erythema | 19 |
| Day 14: Minimal erythema | 1 |
| Day 14: Definite erythema | 0 |
Collected over Up to 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARQ-151 Cream 0.3% | 0/20 (0%) | 0/20 (0%) | 4/20 (20%) |
| Event | ARQ-151 Cream 0.3% |
|---|---|
| Candida infectionInfections and infestations | 1/20 |
| Application site painInjury, poisoning and procedural complications | 1/20 |
| Back painMusculoskeletal and connective tissue disorders | 1/20 |
| HeadacheNervous system disorders | 1/20 |
| Perineal painReproductive system and breast disorders | 1/20 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/20 |
| DermatitisSkin and subcutaneous tissue disorders | 1/20 |
| Perineal erythemaSkin and subcutaneous tissue disorders | 1/20 |
| Age, Continuous(years) | ARQ-151 Cream 0.3% |
|---|---|
| Mean | 8.8 ± 1.61 |
| Sex: Female, Male(Participants) | ARQ-151 Cream 0.3% |
|---|---|
| Female | 7 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | ARQ-151 Cream 0.3% |
|---|---|
| Hispanic or Latino | 12 |
| Not Hispanic or Latino | 8 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | ARQ-151 Cream 0.3% |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 10 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2020 to primary completion in Jan 2022, 13 months.
Results were first posted in Dec 2023, 1 year 11 months after primary completion. A results delay was requested in Dec 2022.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 13 months is close to that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Arcutis Biotherapeutics, Inc. →